Sponsored Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform February 20, 2026Vol.52 No.07By Christine Brown and Enrique Montero
NCI The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades agoLowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” February 13, 2026Vol.52 No.06By Jacquelyn Cobb
Regulatory News CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot February 13, 2026Vol.52 No.06By Claire Marie Porter
Black History MonthCancer History ProjectFree Olopade: “The genetic basis of every cancer, or everything we do, starts in Africa.”For Black History Month, Olopade reflects on mentorship, community, and her career in cancer genetics February 13, 2026Vol.52 No.06By Olufunmilayo I. Olopade, Robert A. Winn and Preston Willett
NCI NCAB ad hoc group approves seven new, reissue concepts February 13, 2026Vol.52 No.06By Sara Willa Ernst
FreeGuest Editorial Science is winning the war on cancer—CMS shouldn’t disarm February 13, 2026Vol.52 No.06By John M. O’Brien
Trials & Tribulations Why infection and immunity matter for Florida’s cancer patients February 13, 2026Vol.52 No.06By Eduardo Sotomayor
Conversation with The Cancer Letter On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center February 06, 2026Vol.52 No.05By Paul Goldberg
NCI Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural researchThe group replaced the NCI Board of Scientific Advisors February 06, 2026Vol.52 No.05By Claire Marie Porter
Black History MonthPodcast Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about” February 06, 2026Vol.52 No.05By Robert A. Winn, Otis W. Brawley and Preston Willett
